Literature DB >> 21183840

Distribution of rotavirus genotypes after introduction of rotavirus vaccines, Rotarix® and RotaTeq®, into the National Immunization Program of Australia.

Carl D Kirkwood1, Karen Boniface, Graeme L Barnes, Ruth F Bishop.   

Abstract

BACKGROUND: Rotavirus vaccines, RotaTeq and Rotarix, were introduced into the Australian National Immunization Program on July 1, 2007. The simultaneous introduction in different Australian states and territories provides a unique opportunity to compare the affect of each vaccine on the types of circulating rotavirus strains. This report describes the rotavirus genotypes responsible for the hospitalization of children during the first 2-year period after vaccine introduction.
METHODS: A total of 764 rotavirus-associated diarrheal cases were collected from children presenting to hospital in 10 Australian centers. Rotavirus genotype was determined using reverse transcription polymerase chain reaction assays.
RESULTS: G1P[8] was the dominant genotype nationally (52%), followed by G2P[4] (19.8%), G9P[8] (12.2%), and G3P[8] (11%). Differences in the prevalence rates of G2P[4] and G3P[8] were seen in the various states. G2P[4] strains were more prevalent in states using Rotarix, whereas G3P[8] strains were more prevalent in states using RotaTeq.
CONCLUSIONS: Differences in rotavirus genotypes were observed across Australia, which suggest that different immune pressures are exerted by the different vaccines, but do not necessarily imply lack of protection by either vaccine. These differences may simply be related to the variation that can occur because of natural annual fluctuation in rotavirus strain prevalence.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21183840     DOI: 10.1097/INF.0b013e3181fefd90

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  39 in total

1.  Modeling rotavirus strain dynamics in developed countries to understand the potential impact of vaccination on genotype distributions.

Authors:  Virginia E Pitzer; Manish M Patel; Ben A Lopman; Cécile Viboud; Umesh D Parashar; Bryan T Grenfell
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-14       Impact factor: 11.205

Review 2.  New insights into rotavirus vaccines.

Authors:  Chiara Mameli; Valentina Fabiano; Gian Vincenzo Zuccotti
Journal:  Hum Vaccin Immunother       Date:  2012-08-01       Impact factor: 3.452

Review 3.  Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines.

Authors:  Olufemi Samuel Folorunso; Olihile M Sebolai
Journal:  Vaccines (Basel)       Date:  2020-06-27

4.  First assessment of all-cause acute diarrhoea and rotavirus-confirmed cases following massive vaccination in Argentina.

Authors:  J I Degiuseppe; J A Stupka
Journal:  Epidemiol Infect       Date:  2018-07-13       Impact factor: 2.451

5.  Effect of monovalent rotavirus vaccine on rotavirus disease burden and circulating rotavirus strains among children in Morocco.

Authors:  Mohammed Benhafid; Nezha Elomari; Meryem Azzouzi Idrissi; Ahmed Rguig; Jon R Gentsch; Umesh Parashar; Rajae Elaouad
Journal:  J Med Virol       Date:  2015-03-05       Impact factor: 2.327

6.  Rotavirus vaccines in Israel: Uptake and impact.

Authors:  Khitam Muhsen; Daniel Cohen
Journal:  Hum Vaccin Immunother       Date:  2017-03-10       Impact factor: 3.452

7.  Monitoring Shedding of Five Genotypes of RotaTeq Vaccine Viruses by Genotype-Specific Real-Time Reverse Transcription-PCR Assays.

Authors:  Yuki Higashimoto; Masaru Ihira; Yu Miyazaki; Ayumi Kuboshiki; Sayaka Yoshinaga; Hiroyuki Hiramatsu; Ryota Suzuki; Masafumi Miyata; Hiroki Miura; Satoshi Komoto; Jun Yukitake; Koki Taniguchi; Yoshiki Kawamura; Tetsushi Yoshikawa
Journal:  J Clin Microbiol       Date:  2018-05-25       Impact factor: 5.948

8.  Genetic analyses reveal differences in the VP7 and VP4 antigenic epitopes between human rotaviruses circulating in Belgium and rotaviruses in Rotarix and RotaTeq.

Authors:  Mark Zeller; John T Patton; Elisabeth Heylen; Sarah De Coster; Max Ciarlet; Marc Van Ranst; Jelle Matthijnssens
Journal:  J Clin Microbiol       Date:  2011-12-21       Impact factor: 5.948

9.  Treatment and prevention of rotavirus infection in children.

Authors:  Penelope H Dennehy
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725

10.  Potential safety issues and other factors that may affect the introduction and uptake of rotavirus vaccines.

Authors:  N Aliabadi; J E Tate; U D Parashar
Journal:  Clin Microbiol Infect       Date:  2016-04-26       Impact factor: 8.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.